The American Lung Association announced on May 6 the launch of the COPD-OMA trial, a national clinical research study conducted through its Airways Clinical Research Centers. The study will investigate whether omalizumab, a medication already approved by the Food and Drug Administration for asthma and allergic diseases, can help reduce flare-ups in people with chronic obstructive pulmonary disease (COPD) who are sensitive to common indoor allergens. Funding for the study comes from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases.
COPD flare-ups can lead to emergency room visits, hospital stays, and long-term declines in lung function. The new trial will examine if adding omalizumab to standard COPD care can decrease these episodes and improve quality of life for patients who have both COPD and allergies.
“COPD remains a leading cause of death and disability in the United States, and many people with COPD continue to experience dangerous and disruptive flare-ups despite current treatments,” said Harold Wimmer, President and CEO of the American Lung Association. “Through this important research, we aim to determine whether an existing, proven medication could offer new hope for people living with COPD and allergies. This study has the potential to significantly improve quality of life for millions of people.”
The Airways Clinical Research Centers network is recruiting participants at sites across the country. Those interested in participating or learning more about eligibility can visit their website or call 1‑800‑LUNGUSA.
The American Lung Association has supported research that contributed to advancements in lung disease treatment; it also extends its reach nationwide through local offices and community programs aimed at improving lung health according to the official website.
Broader implications include potential improvements in how certain types of COPD are managed if this approach proves effective. The association continues its work saving lives through research, education, advocacy efforts focused on lung health according to the official website.
